Vertex Pharmaceuticals Incorporated (VRTX) Earnings Call Transcripts
Vertex Pharmaceuticals Incorporated's Latest Earnings Call - July 6, 2026
In the second quarter of 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, which is expected to enhance Vertex's revenue growth and diversify its portfolio. The acquisition includes promising assets such as PALSONIFY, which has shown strong early momentum in the U.S. with $10.3 million in net product revenue, and Atumelnant, which has multibillion-dollar potential in treating congenital adrenal hyperplasia (CAH). Management highlighted that combined peak sales potential for these assets exceeds $5 billion, positioning Vertex for sustained double-digit revenue growth.
Reported metrics
| Metric | Value |
|---|---|
| Revenue from PALSONIFY | $10.3 million (positive) |
| Acquisition Cost | $10 billion (neutral) |
| Peak Sales Potential | $5 billion (positive) |
| Payer Coverage for PALSONIFY | 60% (positive) |
| Accretive Timeline | 2029 (neutral) |
Guidance from management
Management indicated that they will provide updated 2026 guidance at the time of closing the acquisition, maintaining a cautious outlook on immediate financial impacts.
What management said
Yes. Salveen, briefly, PALSONIFY has been approved in Europe in April earlier this year. And without sort of prejudging exactly what we would do, our plan would be to conduct a global launch of PALSONIFY beyond, of course, the excellent launch that the Crinetics team are executing here in the U.S. right now.
Yes. We've looked at the totality of available data generated to date with Atumelnant in all of the indications. So that means CAH as well as in the early study in ACTH-dependent Cushing's. What we see is minor elevations. I believe there were a handful of cases, I think 7 actually to be exact, of minor elevations in LFTs. There are no cases of LFTs plus bilirubin. There -- most of the cases, 6 of the 7 resolved with...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for Atumelnant, particularly in relation to switching from existing therapies. There were also questions about the high acquisition premium and the timing of adding a fifth pillar to Vertex's portfolio amidst ongoing launches.
Main topics on the call
- Acquisition of Crinetics Pharmaceuticals — Vertex announced the acquisition of Crinetics for $85 per share, totaling approximately $10 billion. CEO Reshma Kewalramani stated, "Crinetics is an excellent strategic fit for Vertex with its focus on serious diseases i...
- PALSONIFY Launch Success — PALSONIFY generated $10.3 million in net product revenue in its second quarter post-launch, capturing a 40% to 50% share of new-to-brand prescriptions. Management noted, "We see blockbuster potential for PALSONIFY," citi...
- Atumelnant's Market Potential — Atumelnant is positioned as a multibillion-dollar opportunity in CAH and is currently enrolling in Phase III trials. Management emphasized, "We believe Atumelnant achieves the previously unattainable holy grail of CAH ma...
- Financial Impact of Acquisition — The acquisition is expected to be accretive to Vertex's non-GAAP operating income by 2029, with a revenue profile that supports sustained double-digit growth. CFO Charlie Wagner stated, "The financial case is straightfor...
Read the full Vertex Pharmaceuticals Incorporated transcript (July 6, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 79 calls on record spanning January 13, 2020 to July 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 79 Vertex Pharmaceuticals Incorporated earnings call transcripts on record, spanning January 13, 2020 to July 6, 2026. Based on this history, Vertex Pharmaceuticals Incorporated reports quarterly. The most recent call on file is dated July 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VRTX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 79
- First call
- January 13, 2020
- Most recent
- July 6, 2026
- Reporting cadence
- quarterly